Pseudo-Leptomeningeal Contrast Enhancement at 3T in Pediatric Patients Sedated by Propofol

A M McKinney1, A Chacko Achanaril2, B Knoll3

  • 1From the Department of Radiology (A.M.M., A.C.A., D.R.N.), Neuroradiology Division, University of Minnesota, Minneapolis, Minnesota mckinrad@umn.edu.

Insights

Propofol sedation can cause leptomeningeal contrast enhancement in young children during MRI. This enhancement is more common with spin-echo T1WI sequences and is not indicative of disease.

Area of Science:

  • Neuroradiology
  • Pediatric Imaging
  • Pharmacology

Background:

  • Propofol is a sedative that affects cerebral perfusion by reducing oxygen metabolism.
  • Young children frequently receive intravenous sedation for Magnetic Resonance (MR) imaging procedures.
  • Understanding contrast enhancement patterns in pediatric MR imaging is crucial for accurate diagnosis.

Purpose of the Study:

  • To evaluate the degree of leptomeningeal contrast enhancement on 3T postcontrast brain MR imaging in children sedated with propofol.
  • To determine if this enhancement correlates with imaging sequence, sedation dosage, or patient demographics (age, weight).

Main Methods:

  • A retrospective review of 43 children (1-5 years) who underwent 3T postcontrast brain MR imaging with propofol sedation.
  • Contrast enhancement was assessed using gradient-echo T1-weighted imaging (T1WI) and spin-echo T1WI sequences.
  • Three neuroradiologists graded enhancement, and interobserver reliability was calculated.

Main Results:

  • Leptomeningeal contrast enhancement was significantly greater on spin-echo T1WI compared to gradient-echo T1WI (P < .0001).
  • Enhancement showed a moderate inverse correlation with patient age and weight (P = .003-.032).
  • Sedation dosage, duration, and timing of contrast administration did not correlate with enhancement (P > .05).

Conclusions:

  • Leptomeningeal contrast enhancement is more frequent and pronounced on 3T spin-echo T1WI in propofol-sedated children.
  • This finding, termed "pseudo"-leptomeningeal enhancement, should not be misdiagnosed as pathology.
  • The phenomenon may be linked to propofol-induced vasodilation and is more prominent in younger/smaller children.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
317
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
237
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
305
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
1.6K
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
1.1K